In the cannabis plant, cannabigerol (CBG) exists in the form of its acidic precursor, CBGA (cannabigerolic acid). CBGA is the chemical starting point from which the plant synthesizes THCA, CBDA, and CBCA — the precursors to THC, CBD, and CBC. By the time most cannabis plants mature, the majority of CBGA has been converted into other cannabinoids, leaving CBG at levels typically below 1% of the plant's cannabinoid content. This scarcity, and the cost of producing CBG-rich extracts, is why it has lagged behind CBD in market development — and why it is now attracting serious scientific attention.
CBG's Pharmacological Profile
CBG interacts with the endocannabinoid system differently than CBD or THC. It acts as a partial agonist at CB1 and CB2 receptors, an alpha-2 adrenergic receptor agonist, and a serotonin 5-HT1A receptor antagonist — a profile distinct from CBD. It also demonstrates activity at TRPA1 channels, relevant to pain and inflammation signaling.
Antibacterial Properties
One of the most striking findings in CBG research is its antibacterial activity. A 2020 study in ACS Infectious Diseases found CBG to be highly effective against methicillin-resistant Staphylococcus aureus (MRSA) biofilms — a notoriously drug-resistant infection. The researchers noted CBG's mechanism was distinct from conventional antibiotics, raising the prospect of a novel antibacterial scaffold from cannabis.
Inflammatory Bowel Disease
A 2013 study in Biochemical Pharmacology examined CBG's effects in a mouse model of inflammatory bowel disease. CBG reduced inflammation markers, attenuated the extent of colitis, and reduced nitric oxide production in macrophages. The authors concluded CBG should be 'considered for clinical experimentation in IBD patients.'
Neuroprotection
A 2015 study in Neurotherapeutics found CBG to be neuroprotective in a mouse model of Huntington's disease, reducing neuroinflammation and oxidative stress while improving motor deficits. This aligns with CBG's known antioxidant activity and its modulation of inflammatory signaling pathways.
Appetite and Metabolism
Research in Psychopharmacology found CBG to stimulate appetite in rats without the psychoactive effects of THC. For patients experiencing appetite loss from chemotherapy, HIV treatment, or metabolic conditions, this represents a clinically interesting non-psychoactive alternative.
I started adding CBG to my CBD regimen when I read about the research on gut inflammation. I have Crohn's, and the combination has been the most significant thing I've tried outside of medication. I'm not in remission, but my symptom frequency is markedly better. — CBG consumer, 38, Denver
The Commercial Frontier
CBG is more expensive to produce than CBD because harvesting it requires cultivating CBG-dominant strains (which produce less total biomass) or harvesting immature plants before CBGA conversion occurs. As selective breeding for CBG-dominant varieties improves and as extraction technology advances, costs are declining. The brands building CBG products now — particularly in the gut health, focus, and antibacterial applications — are entering ahead of the mainstream.